Composition of metagen preparation of bifidobacterium longum subsp.infantis and medicinal and edible mixture and application of composition in regulating blood fat and blood sugar, protecting heart and cerebral vessels and protecting liver and gall

Abstract

The invention belongs to the technical field of probiotics, and particularly relates to a composition of a metagen preparation of bifidobacterium longum subsp.infantis and a medicinal and edible mixture and application of the composition in regulating blood fat and blood sugar, protecting heart and cerebral vessels and protecting liver and gall. The composition disclosed by the invention comprises a metagen preparation of the bifidobacterium longum subsp. Infantis NKU FB3-14 and a mixture with homology of medicine and food. The traditional Chinese medicine composition can effectively relieve glucose and lipid metabolism disorder induced by high-fat and high-cholesterol diet, and can better relieve the glucose and lipid metabolism disorder caused by the high-fat and high-cholesterol diet and protect liver cells by combining with a medicinal and edible mixture and adopting natural plant components with metabolic regulation and heart and cerebral vessel protection effects as adjuvant therapy. Therefore, the pharmaceutical composition has an important application prospect in preventing and treating hyperlipidemia and relieving cardiovascular and cerebrovascular injury caused by metabolic dysfunction.

Description

Technical Field

[0001] The present invention belongs to the technical field of probiotics, and specifically relates to a composition of postbiotics of Bifidobacterium longum subsp. infantis and a mixture of medicated and edible homologous substances, and its application in regulating blood lipid and blood glucose, protecting the cardiovascular and cerebrovascular systems, and protecting the liver and gallbladder. Background Art

[0002] With the transformation of modern dietary structure and lifestyle, glycolipid metabolic dysfunction has become an important threat to global health. Long-term high-fat and high-cholesterol diet leads to disorders of lipid metabolism in the body and reduced insulin sensitivity, directly causing metabolic abnormalities such as hyperlipidemia and hyperglycemia. These metabolic imbalances not only significantly increase the risk of cardiovascular diseases such as atherosclerosis, coronary heart disease, and hypertension, but also exacerbate vascular sclerosis and myocardial injury through mechanisms such as chronic inflammation and endothelial damage. In addition, glycolipid metabolic dysfunction is also closely related to cerebrovascular diseases, including cerebral ischemic injury, neuroinflammatory response, and cognitive decline. The chronic low-grade inflammation and oxidative stress caused by hyperlipidemia and metabolic disorders not only lead to fibrosis of the cardiovascular system and vascular endothelial dysfunction, but also cause damage to the central nervous system, manifested as decreased learning ability, memory impairment, and increased risk of cognitive degenerative diseases.

[0003] In recent years, the prevention and treatment of cardiovascular and cerebrovascular diseases related to metabolic disorders by improving the intestinal microecological balance have gradually received attention. However, at present, the improvement of postbiotics of probiotics on glycolipid metabolic dysfunction and cardiovascular and cerebrovascular damage induced by high-fat and high-cholesterol diet still needs to be further studied. Summary of the Invention

[0004] The purpose of the present invention is to provide a composition of postbiotics of Bifidobacterium longum subsp. infantis and a mixture of medicated and edible homologous substances, and its application in regulating blood lipid and blood glucose, protecting the cardiovascular and cerebrovascular systems, and protecting the liver and gallbladder, and the composition has the efficacy of improving glycolipid metabolism and protecting the cardiovascular and cerebrovascular systems.

[0005] The present invention also provides a composition of a postbiotic preparation of Bifidobacterium longum subsp. Infantis and a medicine-food mixture, comprising a postbiotic preparation of Bifidobacterium longum subsp. Infantis NKUFB3-14 and a medicine-food mixture; the preservation number of the Bifidobacterium longum subsp. Infantis NKU FB3-14 is CGMCC No. 25762, the preservation unit is the General Microbiology Center of the China Culture Collection Administration of Microorganisms, and the preservation date is September 21, 2022; the postbiotic preparation of the Bifidobacterium longum subsp. Infantis NKU FB3-14 comprises a heat-inactivated bacterial solution of Bifidobacterium longum subsp. Infantis NKU FB3-14, a heat-inactivated bacterial body in the bacterial solution, or a heat-inactivated supernatant in the bacterial solution; the Bifidobacterium longum subsp. Infantis in the bacterial solution of NKUFB3-14 contains Bifidobacterium longum subsp. Infantis NKU The concentration of FB3-14 was 1×10 8 ~3×10 9 CFU / mL; in terms of weight, the medicine-food mixture includes the following raw materials: 10-20 parts of ginseng, 10-20 parts of longan pulp, 10-20 parts of poria cocos, 10-20 parts of lotus leaves, 5-15 parts of yam, 5-15 parts of coix seed, 5-15 parts of polygonatum, 5-15 parts of malt, 5-15 parts of tangerine peel, 5-15 parts of white hyacinth bean and 4-6 parts of hawthorn.

[0006] Preferably, the postbiotic preparation of Bifidobacterium longum subspecies infantis NKUFB3-14 comprises a heat-inactivated product of bacteria in a bacterial solution of Bifidobacterium longum subspecies infantis NKU FB3-14; the heat-inactivated product is further subjected to vacuum freeze-drying; the concentration of Bifidobacterium longum subspecies infantis NKU FB3-14 in the bacterial solution of Bifidobacterium longum subspecies infantis NKU FB3-14 is 2×10 9 ~3×10 9 CFU / mL.

[0007] Preferably, the mass ratio of the postbiotic preparation of Bifidobacterium longum subspecies infantis NKU FB3-14 and the medicine-food mixture is (2-4):1.

[0008] The present invention also provides the use of the composition described in the above scheme in preparing food.

[0009] Preferably, the food includes food that helps to improve sugar and lipid metabolism.

[0010] The glucose and lipid metabolism includes the glucose and lipid metabolism caused by a high-fat and high-cholesterol diet.

[0011] Preferably, the improvement of glycolipid metabolism includes one or more of reducing body weight, controlling weight gain, reducing blood glucose content, reducing triglyceride content, reducing cholesterol content, reducing appetite, increasing food energy conversion efficiency, reducing organ weight, reducing epididymal fat content, inhibiting intestinal fat absorption, inhibiting intestinal cholesterol absorption, reducing adipocyte area, increasing serum leptin level, protecting hepatocytes, regulating bile acid metabolism, inhibiting bile acid reabsorption, and improving intestinal flora.

[0012] Preferably, the organs include the liver and / or the epididymis.

[0013] The present invention also provides the use of the composition according to the above solution in the preparation of a drug for preventing, treating and / or alleviating diseases; the diseases include one or more of obesity, glycolipid metabolism dysfunction, intestinal inflammation, intestinal flora imbalance, hyperlipidemia and cardiovascular and cerebrovascular diseases.

[0014] Preferably, preventing, treating and / or alleviating cardiovascular and cerebrovascular diseases includes one or more of reducing the level of cardiovascular risk factors, increasing the level of NO in serum, reducing cardiovascular and cerebrovascular damage, alleviating impaired vascular function, promoting vasodilation and blood flow improvement, inhibiting myocardial cell fibrosis, protecting the nervous system, repairing the blood-brain barrier, and improving brain inflammation.

[0015] Beneficial effects:

[0016] The present invention provides a composition of a postbiotic preparation and a mixture of medicated and edible homologous substances of Bifidobacterium longum subsp. infantis, including a postbiotic preparation of Bifidobacterium longum subsp. infantis NKUFB3-14 and a mixture of medicated and edible homologous substances; the preservation number of Bifidobacterium longum subsp. infantis NKU FB3-14 is CGMCC No. 25762; calculated by mass parts, the mixture of medicated and edible homologous substances includes the following raw materials: 10-20 parts of ginseng, 10-20 parts of longan pulp, 10-20 parts of poria cocos, 10-20 parts of lotus leaf, 5-15 parts of Chinese yam, 5-15 parts of coix seed, 5-15 parts of polygonatum odoratum, 5-15 parts of malt, 5-15 parts of tangerine peel, 5-15 parts of white hyacinth bean, and 4-6 parts of hawthorn. The composition of the present invention includes a postbiotic preparation of Bifidobacterium longum subsp. infantis NKU FB3-14 and a mixture of medicated and edible homologous substances. The present invention can effectively alleviate the glycolipid metabolism disorder induced by high-fat and high-cholesterol diet. Combined with the mixture of medicated and edible homologous substances, using natural plant components with metabolic regulation and cardiovascular protection effects as adjuvant treatment can better reduce the glycolipid metabolism disorder caused by high-fat and high-cholesterol diet and alleviate chronic inflammatory response, thus having important application prospects for the prevention and treatment of hyperlipidemia and the alleviation of cardiovascular and cerebrovascular injuries caused by metabolic dysfunction. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] In order to more clearly illustrate the technical solutions in the embodiments of the present invention or the prior art, the following will briefly introduce the drawings required to be used in the embodiments.

[0018] Figure 1 Results diagram of the effects of postbiotic preparations of different forms of Bifidobacterium longum subsp. infantis NKUFB 3-14 on the body weight of model mice;

[0019] Figure 2 Results diagram of the effects of postbiotic preparations of different forms of Bifidobacterium longum subsp. infantis NKUFB 3-14 on glucose (A), total cholesterol (B), and triglyceride (C) in the serum of model mice;

[0020] Figure 3 Results diagram of the percentage of the binding rate of different compounding ratios of postbiotic preparations and the mixture of medicated and edible homologous substances with taurocholate (A) and glycocholate (B);

[0021] Figure 4 Results diagram of the effects of the composition of the postbiotic preparation of Bifidobacterium longum subsp. infantis NKU FB3-14 and the mixture of medicated and edible homologous substances on the body weight of model mice;

[0022] Figure 5Results graph of the effects of the postbiotic preparation of Bifidobacterium longum subsp. infantis NKU FB3-14 and the medicine and food homology mixture composition on the daily food intake (A), average energy intake (B), and food utilization rate (C) of model mice;

[0023] Figure 6 Results graph of the effects of the postbiotic preparation of Bifidobacterium longum subsp. infantis NKU FB3-14 and the medicine and food homology mixture composition on the liver weight (A) and epididymal fat weight (B) of model mice;

[0024] Figure 7 Results graph of the effects of the postbiotic preparation of Bifidobacterium longum subsp. infantis NKU FB3-14 and the medicine and food homology mixture composition on glucose, total cholesterol, triglyceride, high-density lipoprotein (HDL), and low-density lipoprotein (LDL) in the serum of model mice;

[0025] Figure 8 Results graph of the effects of the postbiotic preparation of Bifidobacterium longum subsp. infantis NKU FB3-14 and the medicine and food homology mixture composition on the intestinal fat absorption ability of model mice;

[0026] Figure 9 Results graph of the effects of the postbiotic preparation of Bifidobacterium longum subsp. infantis NKU FB3-14 and the medicine and food homology mixture composition on the morphology of epididymal fat (A-F) (H&E stained pathological sections) and adipocyte area (E) of model mice;

[0027] Figure 10 Results graph of the effects of the postbiotic preparation of Bifidobacterium longum subsp. infantis NKU FB3-14 and the medicine and food homology mixture composition on the leptin level in the serum of model mice;

[0028] Figure 11 Results graph of the effects of the postbiotic preparation of Bifidobacterium longum subsp. infantis NKU FB3-14 and the medicine and food homology mixture composition on the liver morphology (A-E) (H&E stained pathological sections) of model mice;

[0029] Figure 12 Results graph of the effects of the postbiotic preparation of Bifidobacterium longum subsp. infantis NKU FB3-14 and the medicine and food homology mixture composition on liver lipid deposition (A-E) (oil red stained pathological sections) of model mice;

[0030] Figure 13 Results graph of the effects of the postbiotic preparation of Bifidobacterium longum subsp. infantis NKU FB3-14 and the medicine and food homology mixture composition on the levels of alanine aminotransferase (ALT) (A) and aspartate aminotransferase (AST) (B) in the liver tissue of model mice;

[0031] Figure 14Results graph of the effects of the postbiotic preparation of Bifidobacterium longum subsp. infantis NKU FB3-14 and the food-medicinal homologous mixture composition on cardiovascular risk factors in model mice;

[0032] Figure 15 Results graph of the effects of the postbiotic preparation of Bifidobacterium longum subsp. infantis NKU FB3-14 and the food-medicinal homologous mixture composition on the serum nitric oxide (NO) level in model mice;

[0033] Figure 16 Results graph of the effects of the postbiotic preparation of Bifidobacterium longum subsp. infantis NKU FB3-14 and the food-medicinal homologous mixture composition on the morphology of cardiomyocytes (A-E) (pathological sections stained with H&E) in model mice;

[0034] Figure 17 Results graph of the effects of the postbiotic preparation of Bifidobacterium longum subsp. infantis NKU FB3-14 and the food-medicinal homologous mixture composition on cardiomyocyte fibrosis (A-E) (pathological sections stained with Masson) in model mice;

[0035] Figure 18 Results graph of the effects of the postbiotic preparation of Bifidobacterium longum subsp. infantis NKU FB3-14 and the food-medicinal homologous mixture composition on the injury of Nissl bodies (A-E) (pathological sections stained with Nissl) in the brains of model mice;

[0036] Figure 19 Results graph of the effects of the postbiotic preparation of Bifidobacterium longum subsp. infantis NKU FB3-14 and the food-medicinal homologous mixture composition on the levels of inflammatory factors IL-1β (A) and TNF-α (B) in the brains of model mice;

[0037] Figure 20 Results graph of the effects of the postbiotic preparation of Bifidobacterium longum subsp. infantis NKU FB3-14 and the food-medicinal homologous mixture composition on the intestinal flora (A-C) in model mice;

[0038] Figure 21 Results graph of the effects of the postbiotic preparation of Bifidobacterium longum subsp. infantis NKUFB3-14 and the food-medicinal homologous mixture composition on the functional clustering of the intestinal flora in model mice;

[0039] Figure 22 Results graph of the effects of the postbiotic preparation of Bifidobacterium longum subsp. infantis NKUFB3-14 and the food-medicinal homologous mixture composition on the bile acid level (A) and bile acid synthesis (B) in the livers of model mice;

[0040] Figure 23 Results graph of the effects of the postbiotic preparation of Bifidobacterium longum subsp. infantis NKUFB3-14 and the food-medicinal homologous mixture composition on the bile acid levels in the ileum (A) and serum (B) of model mice;

[0041] Figure 24 Percentage result graph of the binding rates of postbiotics preparation of Bifidobacterium longum subsp. infantis NKUFB3-14 and the homologous mixture of medicine and food before and after deleting the main components to taurocholate (A) and glycocholate (B);

[0042] Figure 25 Percentage result graph of the binding rates of different postbiotics preparations of Bifidobacterium longum subsp. infantis and the homologous mixture of medicine and food to taurocholate (A) and glycocholate (B). Detailed implementation mode

[0043] The present invention provides a composition of a postbiotics preparation of Bifidobacterium longum subsp. infantis and a homologous mixture of medicine and food, including a postbiotics preparation of Bifidobacterium longum subsp. infantis NKUFB3-14 and a homologous mixture of medicine and food; the preservation number of Bifidobacterium longum subsp. infantis NKUFB3-14 is CGMCC No. 25762; the postbiotics preparation of Bifidobacterium longum subsp. infantis NKUFB3-14 includes the heat-inactivated product of the bacterial liquid of Bifidobacterium longum subsp. infantis NKUFB3-14, the heat-inactivated product of the bacterial cells in the bacterial liquid or the heat-inactivated product of the supernatant in the bacterial liquid; the concentration of Bifidobacterium longum subsp. infantis NKUFB3-14 in the bacterial liquid of Bifidobacterium longum subsp. infantis NKUFB3-14 is 1×10 8 ~3×10 9 CFU / mL; calculated by mass, the homologous mixture of medicine and food includes the following raw materials: 10-20 parts of ginseng, 10-20 parts of longan pulp, 10-20 parts of poria cocos, 10-20 parts of lotus leaf, 5-15 parts of Chinese yam, 5-15 parts of coix seed, 5-15 parts of polygonatum odoratum, 5-15 parts of malt, 5-15 parts of tangerine peel, 5-15 parts of white hyacinth bean and 4-6 parts of hawthorn.

[0044] In the specific implementation process of the present invention, the composition is composed of a postbiotics preparation of Bifidobacterium longum subsp. infantis NKUFB3-14 and a homologous mixture of medicine and food.

[0045] In the present invention, Bifidobacterium longum subsp. infantis NKUFB3-14 has been disclosed in Chinese Patent CN116286551A, and it has been proved by experiments that Bifidobacterium longum subsp. infantis NKUFB3-14 is a safe strain and can be used in human and animal bodies.

[0046] In the specific implementation process of the present invention, the postbiotic preparation of Bifidobacterium longum subsp. infantis NKU FB3-14 includes the heat-inactivated product of the bacteria in the bacterial liquid of Bifidobacterium longum subsp. infantis NKU FB3-14, which can better control weight gain and more effectively regulate the glycolipid-related indexes in serum; the heat-inactivated product is also subjected to vacuum freeze-drying; the vacuum degree of the vacuum freeze-drying is 10-100 Pa; the temperature of the vacuum freeze-drying is -40 to -20 °C; the time of the vacuum freeze-drying is 10-14 h; the postbiotic preparation is a solid preparation; the water content of the postbiotic preparation is ≤5%.

[0047] In one embodiment of the present invention, the concentration of Bifidobacterium longum subsp. infantis NKU FB3-14 in the bacterial liquid of Bifidobacterium longum subsp. infantis NKU FB3-14 is 2×10 9 ~3×10 9 CFU / mL.

[0048] In another embodiment of the present invention, the concentration of Bifidobacterium longum subsp. infantis NKU FB3-14 in the bacterial liquid of Bifidobacterium longum subsp. infantis NKU FB3-14 is 1×10 9 ~1.5×10 9 CFU / mL.

[0049] In the specific implementation process of the present invention, the preparation method of the bacterial liquid of Bifidobacterium longum subsp. infantis NKU FB3-14 includes the following steps: inoculating Bifidobacterium longum subsp. infantis NKU FB 3-14 into BS liquid medium, and after inoculation, performing anaerobic culture in a constant temperature incubator. When the OD value of the culture solution is 1.5, the bacterial liquid concentration is close to 1×10 10 CFU / mL, and using BS liquid culture medium to adjust the bacterial liquid concentration to 1×10 8 ~3×10 9 CFU / mL; Bifidobacterium longum subsp. infantis NKU FB 3-14 is inoculated into BS liquid medium at an inoculation amount of 5% by volume; the temperature of the anaerobic culture is 37 °C; the time of the anaerobic culture is 20-24 h.

[0050] After obtaining the bacterial liquid, the present invention performs centrifugal solid-liquid separation on the bacterial liquid to obtain the supernatant (live) of Bifidobacterium longum subsp. infantis NKUFB 3-14 and the bacteria body (live) of Bifidobacterium longum subsp. infantis NKU FB 3-14.

[0051] In one embodiment of the present invention, the bacterial liquid of Bifidobacterium longum subsp. infantis NKU FB3-14 is sequentially subjected to heat inactivation and vacuum freeze-drying to obtain a heat-inactivated product of the bacterial liquid, that is, heat-inactivated bacteria body + supernatant.

[0052] In another embodiment of the present invention, the supernatant of the bacterial solution of Bifidobacterium longum subsp. infantis NKU FB3-14 is sequentially heat-inactivated and vacuum-freeze-dried to obtain a heat-inactivated supernatant of the bacterial solution, namely, a heat-inactivated supernatant.

[0053] In another embodiment of the present invention, the bacterial cells in the bacterial liquid of Bifidobacterium longum subsp. infantis NKU FB3-14 are sequentially heat-inactivated and vacuum-freeze-dried to obtain a heat-inactivated product of the bacterial liquid, namely, the heat-inactivated bacterial cells.

[0054] In the specific implementation process of the present invention, the medicine and food mixture is composed of the following raw materials, calculated by mass: 10-20 parts of ginseng, 10-20 parts of longan meat, 10-20 parts of Poria cocos, 10-20 parts of lotus leaves, 5-15 parts of yam, 5-15 parts of coix seed, 5-15 parts of polygonatum, 5-15 parts of malt, 5-15 parts of tangerine peel, 5-15 parts of white hyacinth bean, and 4-6 parts of hawthorn.

[0055] In one embodiment, the amount of ginseng in the composition of the present invention is 10-20 parts by weight, or further 15 parts. In one embodiment, the amount of longan pulp in the composition of the present invention is 10-20 parts by weight, or further 15 parts. In one embodiment, the amount of poria cocos in the composition of the present invention is 10-20 parts by weight, or further 15 parts. In one embodiment, the amount of lotus leaf in the composition of the present invention is 10-20 parts by weight, or further 15 parts. In one embodiment, the amount of yam in the composition of the present invention is 5-15 parts by weight, or further 10 parts. In one embodiment, the amount of coix seed in the composition of the present invention is 5-15 parts by weight, or further 10 parts. In one embodiment, the amount of polygonatum in the composition of the present invention is 5-15 parts by weight, or further 10 parts. In one embodiment, the amount of malt in the composition of the present invention is 5-15 parts by weight, or further 10 parts. In one embodiment, the amount of tangerine peel in the composition of the present invention is 5-15 parts by weight, or further 10 parts. As an embodiment, the mass fraction of white dung bean in the composition of the present invention is 5 to 15 parts, further 10 parts. As an embodiment, the mass fraction of hawthorn in the composition of the present invention is 4 to 6 parts, further 5 parts.

[0056] Compared with the use of postbiotic preparations alone, the addition of the medicine-food mixture significantly reduced the liver triglyceride accumulation, liver CYP7A1 enzyme level and intestinal lipid absorption capacity caused by a high-fat and high-cholesterol diet; and significantly increased the serum nitric oxide (NO) level of the model mice, indicating that the medicine-food mixture has outstanding potential in regulating the body's liver lipid metabolism and vascular endothelial function.

[0057] Among them, ginseng can enhance insulin sensitivity, regulate blood sugar, have antioxidant and anti-inflammatory effects, improve the body's immunity, and help protect cardiovascular function; longan pulp can promote blood circulation, antiplatelet aggregation, reduce blood lipid, have antioxidant and anti-inflammatory effects, and protect cardiovascular and cerebrovascular health; lotus leaf can reduce blood lipid, inhibit fat absorption, promote fat decomposition, and prevent obesity and atherosclerosis; poria can promote diuresis and excrete dampness, regulate the intestinal microenvironment, promote glycolipid metabolism, improve insulin resistance, and enhance immunity; Chinese yam can enhance insulin sensitivity, regulate intestinal flora, promote gastrointestinal function, and has a regulatory effect on glycolipid metabolism; coix seed can reduce blood sugar, lower blood lipid, have anti-inflammatory effects, promote diuresis and excrete dampness, improve lipid metabolism and prevent atherosclerosis; polygonatum odoratum nourishes yin and moistens dryness, improves insulin resistance, regulates blood sugar, and has antioxidant effects to protect the cardiovascular; malt can promote the digestion and absorption of starch, regulate gastrointestinal function, and help balance glycolipid metabolism; tangerine peel can promote digestion, regulate fat metabolism, have antioxidant effects, and protect cardiovascular and cerebrovascular health; white hyacinth bean can strengthen the spleen and dispel dampness, improve insulin resistance, regulate glycolipid metabolism, and improve energy utilization rate; hawthorn can lower blood lipid, reduce blood sugar, promote gastrointestinal peristalsis, improve vascular elasticity, and prevent hypertension and arteriosclerosis.

[0058] Regulating glycolipid metabolism: Ginseng, Chinese yam, lotus leaf, hawthorn and white hyacinth bean jointly promote insulin sensitivity, inhibit fat synthesis, and reduce blood sugar and blood lipid levels; Antioxidant and anti-inflammatory: Longan pulp, poria, polygonatum odoratum and tangerine peel are rich in antioxidant substances, reduce inflammatory reactions, and protect the cardiovascular; Promoting digestion and absorption: Malt, tangerine peel, white hyacinth bean and hawthorn help improve gastrointestinal function and enhance metabolic capacity; Enhancing immunity and protecting blood vessels: Ginseng, longan pulp, poria and coix seed maintain cardiovascular and cerebrovascular health by regulating immune function, anticoagulation and reducing blood lipid. These ingredients are mutually compatible and jointly play a role in improving metabolic syndrome, preventing diabetes and cardiovascular and cerebrovascular diseases by regulating the intestinal microecology, balancing glycolipid metabolism, anti-inflammatory and antioxidant, and improving vascular function.

[0059] The bile salt-binding ability of the composition of the homologous mixture of medicine and food (ginseng, longan pulp, poria, lotus leaf) after deleting the main components and the postbiotics preparation of Bifidobacterium infantis NKU FB3-14 decreased significantly. The bile salt-binding ability of the homologous mixture of medicine and food and the composition of other Bifidobacterium infantis decreased significantly. It shows that the postbiotics preparation of Bifidobacterium infantis NKU FB3-14 and the homologous mixture of medicine and food are the best lipid-lowering active combination.

[0060] In the specific implementation process of the present invention, the preparation method of the homologous mixture of medicine and food includes the following steps:

[0061] Mix the raw materials of the homologous mixture of medicine and food with water, and then soak and decoct them in turn to obtain the water extract of the homologous mixture of medicine and food;

[0062] The water extract of the medicine and food homology is concentrated under reduced pressure to a crude drug content of 1 g / mL to obtain the extract of the medicine and food homology;

[0063] The water extract of the medicine and food homology is freeze-dried and then ground into powder to obtain the mixture of the medicine and food homology.

[0064] In the specific implementation process of the present invention, the mass ratio of the postbiotics preparation of Bifidobacterium longum subsp. infantis NKU FB3-14 to the mixture of the medicine and food homology is (2-4):1, and further preferably 2:1. At this ratio, the combination rate of the composition with glycocholate and taurocholate is the highest.

[0065] In the specific implementation process of the present invention, the preparation method of the composition includes the following steps: mixing the mixture of the medicine and food homology and the postbiotics preparation.

[0066] As an implementation manner, the dosage form of the composition of the present invention can be, but is not limited to, liquid and / or powder, such as solid beverage, liquid beverage, tablet, pill or capsule.

[0067] In the specific implementation process of the present invention, the application of the composition in food.

[0068] In the specific implementation process of the present invention, the food includes food for improving glycolipid metabolism; the food can be a health food.

[0069] In the specific implementation process of the present invention, the glycolipid metabolism includes glycolipid metabolism caused by high-fat and high-cholesterol diet.

[0070] In the specific implementation process of the present invention, the improvement of glycolipid metabolism includes one or more of reducing body weight, controlling body weight gain, reducing blood glucose content, reducing triglyceride content, reducing cholesterol content, reducing appetite, improving food energy conversion efficiency, reducing organ weight, reducing epididymal fat content, inhibiting intestinal fat absorption, inhibiting intestinal cholesterol absorption, reducing fat cell area, increasing serum leptin level, protecting liver cells, regulating bile acid metabolism, inhibiting bile acid reabsorption and improving intestinal flora.

[0071] In the specific implementation process of the present invention, the organ includes liver and / or epididymis.

[0072] The present invention also provides the application of the composition described in the above solution in the preparation of drugs for preventing, treating and / or alleviating diseases; the diseases include one or more of obesity, glycolipid metabolism dysfunction, intestinal inflammation, intestinal flora disorder (intestinal flora structure disorder), hyperlipidemia and cardiovascular and cerebrovascular diseases.

[0073] In the present invention, the disease is induced by diet, further induced by a high-fat and high-cholesterol diet; the cardio-cerebrovascular diseases include cardio-cerebrovascular diseases caused by glycolipid metabolic dysfunction; the cardio-cerebrovascular diseases include, but are not limited to, atherosclerosis, coronary heart disease, hypertension, hyperlipidemia, and metabolic syndrome.

[0074] In the specific implementation process of the present invention, preventing, treating, and / or alleviating cardio-cerebrovascular diseases includes one or more of reducing the level of cardiovascular risk factors, increasing the level of NO in serum, reducing cardio-cerebrovascular damage, alleviating impaired vascular function, promoting vasodilation and blood flow improvement, inhibiting myocardial cell fibrosis, protecting the nervous system, repairing the blood-brain barrier, and improving brain inflammation.

[0075] In the specific implementation process of the present invention, alleviating impaired vascular function includes alleviating impaired vascular endothelial function.

[0076] In the present invention, the composition is used to reduce cardiac inflammatory cell infiltration and ventricular damage, improve myocardial cell fibrosis and histological damage, reduce cardiac inflammatory cell infiltration and ventricular damage, improve myocardial cell fibrosis and histological damage, reduce brain inflammatory factors, improve blood-brain barrier integrity and neuronal damage.

[0077] In the present invention, the intestinal flora dysbiosis includes intestinal flora dysbiosis induced by a high-fat and high-cholesterol diet.

[0078] Next, the technical solutions in the present invention will be clearly and completely described in conjunction with the embodiments in the present invention. Obviously, the described embodiments are only a part of the embodiments of the present invention, rather than all the embodiments. All other embodiments obtained by those of ordinary skill in the art based on the embodiments in the present invention without making creative efforts shall fall within the protection scope of the present invention.

[0079] The components of the culture medium used in the following examples are as follows:

[0080] BS solid medium: peptone 10.0 g / L, liver extract powder 5.0 g / , beef extract powder 3.0 g / L, yeast extract powder 5.0 g / L, tryptone 8.0 g / L, soluble starch 0.5 g / L, sodium chloride 1 g / L, dipotassium hydrogen phosphate 1 g / L, potassium dihydrogen phosphate 1 g / L, glucose 10 g / L, ferric sulfate heptahydrate 0.01 g / L, manganese sulfate 0.005 g / L, L-cysteine 0.5 g / L, and agar 20 g / L.

[0081] BS liquid medium: peptone 10.0 g / L, liver extract powder 5.0 g / , beef extract powder 3.0 g / L, yeast extract powder 5.0 g / L, tryptone 8.0 g / L, soluble starch 0.5 g / L, sodium chloride 1 g / L, dipotassium hydrogen phosphate 1 g / L, potassium dihydrogen phosphate 1 g / L, glucose 10 g / L, ferric sulfate heptahydrate 0.01 g / L, manganese sulfate 0.005 g / L, and L-cysteine 0.5 g / L.

[0082] In the following examples, statistical significance was determined by Student's t-test. The significance levels were set as *p (or *p) < 0.05, **p (or **p) < 0.01, ***p (or ***p) < 0.001, ****p (or ****p) < 0.0001.

[0083] In the following examples, unless otherwise specified, all are conventional methods.

[0084] In the following examples, materials, reagents, etc. used, unless otherwise specified, are commercially available.

[0085] Test Example 1

[0086] 1. Preparation of postbiotics of different forms of Bifidobacterium longum subsp. infantis NKUFB 3-14

[0087] Inoculate Bifidobacterium longum subsp. infantis NKU FB 3-14 into BS liquid medium at an inoculum size of 5% (v / v). After inoculation, incubate anaerobically in a 37 °C constant temperature incubator for 20 - 24 h. When the OD value of the culture broth reaches 1.5, the bacterial concentration is close to 1×10 10 CFU / mL. Use BS liquid culture medium to adjust the bacterial concentration to 2 - 3×10 9 CFU / mL as the culture broth (bacterial suspension). Centrifuge the culture broth at 8000 g for 5 min to separate the supernatant and the bacterial cell precipitate.

[0088] Heat the bacterial suspension in a water bath at 85 °C for 15 min and then perform vacuum freeze-drying to obtain the postbiotics of Bifidobacterium longum subsp. infantis NKUFB 3-14, namely heat-inactivated bacteria + supernatant (heat-inactivated product of the bacterial suspension);

[0089] Heat the supernatant in a water bath at 85 °C for 15 min and then perform vacuum freeze-drying to obtain the postbiotics of Bifidobacterium longum subsp. infantis NKUFB 3-14, namely heat-inactivated supernatant (heat-inactivated product of the supernatant in the bacterial suspension);

[0090] Heat the bacterial cell precipitate in a water bath at 85 °C for 15 min and then perform vacuum freeze-drying to obtain the postbiotics of Bifidobacterium longum subsp. infantis NKU FB 3-14, namely heat-inactivated bacteria (heat-inactivated product of the bacteria in the bacterial suspension).

[0091] 2. Screening of Postbiotics Formulations for Efficiently Improving the Indicators of Mice with Glycolipid Metabolism Disorders

[0092] A mouse model of cardiovascular and cerebrovascular injury (hereinafter referred to as "model") was induced by a 12-week high-fat and high-cholesterol diet (40 kcal% fat, 1.25 gm% cholesterol, 0.5 gm% sodium cholate). A control group (C), a model group (H), and an intervention group (T) were set up. The intervention group (T) was divided into a heat-inactivated bacterial cell group (T1), a heat-inactivated supernatant group (T2), and a heat-inactivated bacterial cell + supernatant group (T3). The postbiotics formulations that could efficiently alleviate the glycolipid metabolism disorders in mice were screened through body weight and blood glycolipid indicators.

[0093] The preparation methods of the above components were the same as those in step 1.

[0094] After 1 week of adaptive feeding, a 12-week intervention period began. Among them, the control group (C) was fed a normal diet (Synerbio SPF-grade experimental mouse maintenance diet SWS9102, its main ingredients: Northeast corn, wheat, imported fish meal, chicken meal, soybean meal, soybean oil, amino acids, vitamins, and minerals); the mice in the model group (H) and the intervention group (T) were fed a high-fat and high-cholesterol diet during the intervention period (formula: 40 kcal% fat, 1.25 gm% cholesterol, 0.5 gm% sodium cholate). During the intervention period, all mice had unrestricted access to food and water; the heat-inactivated bacterial cell group (T1) was gavaged with heat-inactivated bacterial cells, with a daily gavage volume of 0.2 mL; the heat-inactivated supernatant group (T2) was gavaged with heat-inactivated supernatant, with a daily gavage volume of 0.2 mL; the heat-inactivated supernatant group (T3) was gavaged with heat-inactivated bacterial cells + supernatant, with a daily gavage volume of 0.2 mL. The control group (C) and the model group (H) were simultaneously gavaged with an equal volume of BS liquid medium. Gavage was carried out continuously for 12 weeks, and the body weight was measured once a week and the gavage dose was adjusted according to the body weight change. The body weight change was as Figure 1 shown.

[0095] On the last day of the 12-week intervention, mouse fecal samples were collected and stored at -80°C. Subsequently, the mice were fasted for 16 h with free access to water. After fasting, the mice were anesthetized with sodium pentobarbital (1% aqueous solution), and blood samples were collected by orbital blood collection. After the whole blood samples were left standing at room temperature for 4 h, they were centrifuged at 3000 rpm at 4°C for 15 min to collect serum samples. After blood collection, the mice were decapitated, and the jejunum, ileum, colon, liver, fat, brain, and heart tissues of the mice were collected, snap-frozen in liquid nitrogen and stored at -80°C or placed in tissue fixative for histopathological analysis. All animal experiment operations complied with the relevant regulations of the "Regulations on the Administration of Laboratory Animals" in Tianjin.

[0096] by Figure 1It can be seen that after 12 weeks of high-fat and high-cholesterol diet induction, the weight of mice in the model group (H) increased significantly compared with the control group (C), indicating that this model can significantly increase the obesity level of mice. After 4 weeks of intervention, the weight gain of the heat-killed supernatant group (T2) and the heat-killed bacteria group (T1) was significantly lower than that of the control group (C). It is worth noting that compared with other forms of postbiotic preparations, the heat-killed bacteria group (T1) has the most outstanding control over weight gain. The weight of mice induced by a high-fat and high-cholesterol diet for 12 weeks only increased by 2.9g. It can be seen that the most effective form of postbiotic preparation for weight control is heat-killed bacteria (T1).

[0097] By measuring the glycolipid-related indicators in the serum of mice in different groups, it was found that the serum glucose, total cholesterol and triglyceride levels in the control group (C) and intervention group (T) were significantly lower than those in the model group (H) (p<0.01) ( Figure 2 Among them, the serum triglyceride level of the T1 group was significantly lower than that of the T2 group ( Figure 2 C).

[0098] In summary, the most effective postbiotic preparation for controlling the body weight of model mice and regulating serum glycolipid-related indicators is heat-killed bacteria (T1).

[0099] Example 1

[0100] 1. Heat-inactivated bacteria (heat-inactivated bacteria in bacterial solution) were prepared using the method of Experimental Example 1. The concentration of NKUFB 3-14 bacteria before heat inactivation was 1×10 9 ~1.5×10 9 CFU / mL.

[0101] 2. The medicine-food mixture is composed of the following ingredients: 15g of ginseng, 15g of longan meat, 15g of lotus leaf, 15g of Poria cocos, 10g of yam, 10g of coix seed, 10g of polygonatum, 10g of malt, 10g of white hyacinth bean, 10g of tangerine peel and 5g of hawthorn.

[0102] Preparation method:

[0103] The raw materials of the food and medicine mixture are mixed with water, and then soaked and decocted in sequence to obtain a food and medicine water extract; the food and medicine water extract is concentrated under reduced pressure to a crude drug amount of 1 g / mL to obtain a food and medicine extract solution; the obtained food and medicine water extract is freeze-dried and then ground into powder to obtain a food and medicine mixture for later use.

[0104] 3. The heat-inactivated bacteria obtained in step 1 and the medicine-food mixture obtained in step 2 are mixed in a mass ratio of 2:1 to obtain a composition.

[0105] Determination of the Optimal Ratio of Postbiotics Preparation of *Bifidobacterium longum* subsp. *infantis* NKU FB3-14 and Medicinal and Edible Homologous Mixture

[0106] By measuring the differences in the bile salt-binding ability of different ratios of postbiotics preparation (in the form of heat-inactivated bacteria) and medicinal and edible homologous mixture in an in vitro simulated intestinal environment, and then judging the lipid-lowering activity of different ratio combinations, the composition ratio with the strongest lipid-lowering activity was screened out.

[0107] 1. The heat-inactivated bacteria and the medicinal and edible homologous mixture were prepared according to the method of Example 1. The heat-inactivated bacteria and the medicinal and edible homologous mixture were mixed at mass ratios of 4:1, 2:1, 1:1, 1:2, and 1:4 respectively to obtain postbiotics preparation and medicinal and edible homologous mixture compositions with different ratios.

[0108] 2. Standard curves of sodium glycocholate and sodium taurocholate were drawn. Prepare standard solutions of sodium glycocholate and sodium taurocholate with different concentrations (0, 0.5, 1, 1.5, 2, 2.5, 3 μg / mL) in stoppered test tubes, add 6 mL of 60% sulfuric acid solution, mix well, heat in a water bath at 70 °C for 20 min, quickly ice-bath for 5 min, and measure the absorbance at a wavelength of 387 nm by ultraviolet spectrophotometry. Using the absorbance as the ordinate and the bile salt content as the abscissa, draw the standard curves of glycocholate and taurocholate.

[0109] 3. Measure the bile salt-binding ability in an in vitro simulated intestinal environment. Respectively, 3 mL of postbiotics preparation and medicinal and edible homologous mixture compositions with different ratios (4:1, 2:1, 1:1, 1:2, 1:4), 3 mL of 10 mg / mL pepsin solution, and 1 mL of 0.01 mol / L HCl solution were subjected to digestion treatment in a constant temperature oscillator at 37 °C for 1 h to simulate the gastric digestion process. Subsequently, the pH value of the solution was adjusted to 6.3 with 0.1 mol / L NaOH solution, and then 4 mL of 10 mg / mL trypsin was added, and the mixture was digested in a constant temperature oscillator at 37 °C to simulate the intestinal environment for 1 h. 4 mL of 0.4 mmol / L sodium glycocholate or 0.5 mmol / L sodium taurocholate was added to each group of samples. After constant temperature oscillation at 37 °C for 1 h, the mixture was transferred to a centrifuge tube and centrifuged at 4000 r / min for 20 min. The supernatant was taken and the absorbance value was measured at 387 nm by colorimetry. Each sample was measured in parallel 3 times. The remaining sodium glycocholate and sodium taurocholate contents were calculated according to the standard curve. The ratio of the difference between the total amount of added sodium glycocholate or sodium taurocholate and the remaining amount to the total amount was the binding rate, expressed as a percentage. The calculation formula is as follows:

[0110] Bile salt binding rate = (amount of bile salt added - amount of bile salt remaining) / amount of bile salt added × 100%;

[0111] The results showed that the higher the binding rate of bile salts, the better the cholesterol-lowering effect. As can be seen from Figure 3 A and B in Figure 3 , when the ratio of postbiotics to the mixture of medicine and food homologous ingredients is 2:1, the binding rates with glycocholate and taurocholate are the highest, reaching 78% and 84% respectively. Therefore, the optimal ratio of postbiotics to the mixture of medicine and food homologous ingredients was determined to be 2:1.

[0112] Example 3

[0113] Except that the concentration of NKUFB 3-14 strain before heat inactivation was 2-3×10 9 CFU / mL, the rest was the same as in Example 1.

[0114] Example 4 Effect of the composition of postbiotics and the mixture of medicine and food homologous ingredients on improving glycolipid metabolic dysfunction

[0115] 1. Effects of the composition of postbiotics of Bifidobacterium longum subsp. infantis NKUFB3-14 and the mixture of medicine and food homologous ingredients on the body weight, appetite and organ weights of model mice.

[0116] A mouse model of cardiovascular and cerebrovascular injury (hereinafter referred to as "model") was induced by a 12-week high-fat and high-cholesterol diet (40 kcal% fat, 1.25 gm% cholesterol, 0.5 gm% sodium cholate), and a control group (C), a model group (H) and an intervention group were set up. The intervention group was divided into: a heat-inactivated bacterial cell group (J), a mixture of medicine and food homologous ingredients group (Y) and a composition group of postbiotics and the mixture of medicine and food homologous ingredients (Z).

[0117] The preparation methods of the above components were the same as those in Example 3.

[0118] After 1 week of adaptive feeding, a 12-week intervention period began. Among them, the control group (C) was fed with normal feed; the model group (H), the heat-inactivated bacterial cell group (J), the mixture of medicine and food homologous ingredients group (Y), and the composition group of postbiotics and the mixture of medicine and food homologous ingredients (Z) were fed with high-fat and high-cholesterol feed (formula: 40 kcal% fat, 1.25 gm% cholesterol, 0.5 gm% sodium cholate) during the intervention period. All mice were not restricted in food and water intake during the intervention period; the heat-inactivated bacterial cell group (J) was gavaged with heat-inactivated bacterial cells, and the daily gavage volume was 0.2 mL; the mixture of medicine and food homologous ingredients group (Y) was gavaged with the mixture of medicine and food homologous ingredients, and the daily gavage volume was 0.2 mL; the composition group of postbiotics and the mixture of medicine and food homologous ingredients (Z) was gavaged with the composition, and the daily gavage volume was 0.2 mL; the control group (C) and the model group (H) were simultaneously gavaged with an equal volume of BS liquid medium, continuously gavaged for 12 weeks, weighed once a week, and the gavage dose was adjusted in a timely manner according to the body weight change.

[0119] On the last day of the 12-week intervention, mouse fecal samples were collected and stored at -80°C. Subsequently, the mice were fasted for 16 h with free access to water. After fasting, the mice were anesthetized with sodium pentobarbital (1% aqueous solution), and blood samples were collected by orbital blood collection. After blood collection, the mice were decapitated, and jejunum, ileum, colon, liver, adipose tissue, brain, and heart tissues were collected, snap-frozen in liquid nitrogen, stored at -80°C, or placed in tissue fixative for histopathological analysis. All animal experiments were conducted in accordance with the relevant regulations of the "Regulations on the Administration of Laboratory Animals" in Tianjin.

[0120] After 12 weeks of induction with a high-fat and high-cholesterol diet, the body weight of the mice in the model group (H) was significantly higher than that of the control group (C) mice after the 4th week. Moreover, the body weights of the heat-inactivated bacterial cell group (J), the medicine-food homologous mixture group (Y), and the postbiotics and medicine-food homologous mixture composition group (Z) mice were significantly lower than those of the model group (H) mice after the 4th week ( Figure 4 ). It is worth noting that the heat-inactivated bacterial cell group (J) had a better effect on controlling the body weight of the model mice than the medicine-food homologous mixture group (Y), and the postbiotics and medicine-food homologous mixture composition group (Z) had the most obvious decrease in the body weight of the model mice. It can be seen that the postbiotics and medicine-food homologous mixture composition can effectively relieve the obesity symptoms of mice.

[0121] During the 12-week intervention, the feed intake of the mice was recorded weekly. The food utilization rate refers to the ratio of the percentage change in body weight to the energy intake after the mice consumed a certain amount of food. As Figure 5 can be seen, the average energy intake and food utilization rate of the mice in the model group (H) were significantly higher than those of the control group (C) mice. There was no significant difference in the daily food intake and average energy intake between the heat-inactivated bacterial cell group (J), the medicine-food homologous mixture group (Y), and the model group (H) mice. However, the daily food intake and average energy intake of the postbiotics and medicine-food homologous mixture composition group (Z) mice were significantly lower than those of the model group (H) mice. In addition, there was no significant difference in the food utilization rate between the medicine-food homologous mixture group (Y) and the model group (H). The food utilization rates of the heat-inactivated bacterial cell group (J) and the postbiotics and medicine-food homologous mixture composition group (Z) mice were significantly lower than those of the model group (H) mice. In summary, the postbiotics and medicine-food homologous mixture composition can effectively reduce the appetite and food energy conversion efficiency of the model mice.

[0122] After 12 weeks of intervention, the liver tissue and epididymal fat of each sacrificed mouse were collected, and the liver weight and epididymal fat weight were weighed and recorded. As Figure 6It can be seen that the liver and epididymal fat weights of the mice in the model group (H) were significantly higher than those of the mice in the control group (C). The liver and epididymal fat weights of the mice in the heat-inactivated bacterial group (J), the food-medicinal homology mixture group (Y), and the postbiotic preparation and food-medicinal homology mixture composition group (Z) were all lower than those of the model group (H), and the epididymal fat content of the mice in the postbiotic preparation and food-medicinal homology mixture composition group (Z) was the lowest. It can be seen that the postbiotic preparation and food-medicinal homology mixture composition can effectively reduce the organ weights of the model mice.

[0123] 2. Effects of the postbiotic preparation of Bifidobacterium longum subsp. infantis NKU FB3-14 and the food-medicinal homology mixture composition on blood glucose and blood lipid metabolism in model mice.

[0124] After 12 weeks of induction with a high-fat and high-cholesterol diet, the blood glucose level of the mice in the model group (H) was significantly higher than that of the mice in the control group (C) Figure 7 ). The blood glucose levels of the mice in the heat-inactivated bacterial group (J), the food-medicinal homology mixture group (Y), and the postbiotic preparation and food-medicinal homology mixture composition group (Z) were all significantly lower than that of the model group (H), and the blood glucose level of the mice in the postbiotic preparation and food-medicinal homology mixture composition group (Z) was the lowest.

[0125] Similarly, the total cholesterol and triglyceride levels in the serum of the mice in the model group (H) were significantly higher than those of the mice in the control group (C) Figure 7 ). The total cholesterol and triglyceride levels in the serum of the mice in the heat-inactivated bacterial group (J) and the postbiotic preparation and food-medicinal homology mixture composition group (Z) were both significantly lower than that of the model group (H), and the total cholesterol and triglyceride levels in the serum of the mice in the postbiotic preparation and food-medicinal homology mixture composition group (Z) were the lowest.

[0126] After 12 weeks of induction with a high-fat and high-cholesterol diet, the HDL level in the serum of the mice in the model group (H) was significantly lower than that of the mice in the control group (C) Figure 7 ). The HDL levels in the serum of the mice in the heat-inactivated bacterial group (J) and the food-medicinal homology mixture group (Y) were both significantly higher than that of the model group (H), while there was no significant difference in the HDL levels in the serum between the postbiotic preparation and food-medicinal homology mixture composition group (Z) and the model group (H). The LDL level in the serum of the mice in the model group (H) was significantly higher than that of the mice in the control group (C) Figure 7 ). The LDL levels in the serum of the mice in the heat-inactivated bacterial group (J), the food-medicinal homology mixture group (Y), and the postbiotic preparation and food-medicinal homology mixture composition group (Z) were all significantly lower than that of the model group (H).

[0127] In summary, the postbiotic preparation and food-medicinal homology mixture composition can effectively reduce the disorder of glucose and lipid metabolism in the serum of model mice.

[0128] 3. Effects of the postbiotic preparation of Bifidobacterium longum subsp. infantis NKU FB3-14 and the composition of the medicine and food homologous mixture on the intestinal fat absorption ability and adipose tissue metabolism ability of model mice.

[0129] After 12 weeks of induction with a high-fat and high-cholesterol diet, the triglyceride level in the jejunum tissue of mice in the model group (H) was significantly higher than that of mice in the control group (C) Figure 8 ), indicating that the intestinal lipid absorption ability of the cardiovascular model mice induced by a high-fat and high-cholesterol diet was significantly enhanced. The triglyceride level in the jejunum tissue of mice in the heat-inactivated bacterial group (J), the medicine and food homologous mixture group (Y), and the postbiotic preparation and medicine and food homologous mixture composition group (Z) was significantly lower than that of mice in the model group (H), and the triglyceride level in the jejunum tissue of mice in the postbiotic preparation and medicine and food homologous mixture composition group (Z) was the lowest, indicating that the postbiotic and medicine and food homologous mixture composition can effectively inhibit the absorption of dietary fat and cholesterol by the intestinal tissue of mice, thereby reducing the accumulation of lipids in mice.

[0130] The results of pathological section staining showed that compared with mice in the control group (C), the adipocyte volume of mice in the model group (H) increased, showing larger vacuoles, and the sizes of the vacuoles were uneven. A large number of inflammatory cells infiltrating in a corolla-like structure appeared in the adipose stroma ( Figure 9 marked by the black arrow B in), while the adipocytes of mice in the control group (C), the heat-inactivated bacterial group (J), the medicine and food homologous mixture group (Y), and the postbiotic preparation and medicine and food homologous mixture composition group (Z) were closely arranged, relatively small in volume, clear in boundary and uniform in morphology, and no inflammatory cell infiltration was seen ( Figure 9 A, C, D, E in). By statistically analyzing the epididymal adipocyte areas of mice in different groups, it was found that the adipocyte area of mice in the model group (H) was extremely significantly higher than that of the control group (C), and the adipocyte areas of mice in the heat-inactivated bacterial group (J), the medicine and food homologous mixture group (Y), and the postbiotic preparation and medicine and food homologous mixture composition group (Z) were extremely significantly smaller than those of mice in the model group (H) Figure 9 marked by F in).

[0131] After 12 weeks of induction with a high-fat and high-cholesterol diet, the leptin level in the serum of mice in the model group (H) was significantly higher than that of mice in the control group (C) Figure 10 ), indicating that the increase in adipose tissue of the cardiovascular injury mice induced by a high-fat and high-cholesterol diet led to an increase in leptin secretion. The leptin levels in the sera of mice in the heat-inactivated bacterial group (J), the medicine and food homologous mixture group (Y), and the postbiotic preparation and medicine and food homologous mixture composition group (Z) were extremely significantly lower than those of mice in the model group (H), and the leptin level in the serum of mice in the postbiotic preparation and medicine and food homologous mixture composition group (Z) was the lowest.

[0132] 4. Effects of the postbiotic preparation and the composition of the medicine and food homology mixture of Bifidobacterium longum subsp. infantis NKU FB3-14 on liver lipid deposition and liver function injury in model mice.

[0133] The results of pathological section staining showed that after 12 weeks of induction with a high-fat and high-cholesterol diet, compared with the control group (C) mice, the HE results of the liver of the model group (H) mice showed obvious fatty degeneration, with an increase in fat vacuoles in hepatocytes and a vacuolar change at the cell edge. The liver tissue structure of the heat-inactivated bacterial cell group (J), the medicine and food homology mixture group (Y), and the postbiotic preparation and medicine and food homology mixture composition group (Z) mice was relatively regular, the hepatocytes were arranged neatly, the sizes of the cell nuclei were uniform, and no obvious fatty degeneration or inflammatory reaction was observed ( Figure 11 ).

[0134] The results of pathological section staining showed that after 12 weeks of induction with a high-fat and high-cholesterol diet, compared with the control group (C) mice, the liver of the model group (H) mice showed bright red staining after Oil Red staining, which reflected a large amount of fat accumulation in the liver, especially an increase in fat vesicles in hepatocytes. The liver sections of the heat-inactivated bacterial cell group (J), the medicine and food homology mixture group (Y), and the postbiotic preparation and medicine and food homology mixture composition group (Z) mice had no obvious fat staining, indicating that there was almost no neutral fat deposition in hepatocytes ( Figure 12 )

[0135] After 12 weeks of induction with a high-fat and high-cholesterol diet, the levels of ALT and AST in the liver of the model group (H) mice were significantly higher than those of the control group (C) mice ( Figure 13 ), indicating that the high-fat and high-cholesterol diet induced damage to hepatocytes in mice. Among them, the ALT level in the liver of the postbiotic preparation and medicine and food homology mixture composition group (Z) mice was significantly lower than that of the model group (H) mice, while there was no significant difference between the other intervention group mice and the model group (H) mice. The AST levels in the liver of the heat-inactivated bacterial cell group (J) and the postbiotic preparation and medicine and food homology mixture composition group (Z) mice were significantly lower than those of the model group (H) mice, while there was no significant difference between the medicine and food homology mixture group (Y) mice and the model group (H) mice. Thus, it can be seen that compared with other intervention groups, the postbiotic preparation and medicine and food homology mixture composition group can effectively protect the integrity of hepatocytes and prevent hepatocyte injury induced by a high-fat and high-cholesterol diet.

[0136] 5. Effects of the postbiotic preparation and the composition of the medicine and food homology mixture on cardiovascular risk factors and vascular function injury.

[0137] Cardiovascular risk factors (TG / HDL, HDL / LDL, TC / HDL ratios) are a common indicator for evaluating metabolic syndrome, diabetes, and cardiovascular diseases. A high TG / HDL ratio is considered an independent risk factor for atherosclerosis and coronary heart disease, and a higher TG / HDL ratio is usually associated with an increased cardiovascular risk.

[0138] The results showed that the TG / HDL, HDL / LDL, and TC / HDL ratios of mice in the heat-inactivated bacterial cell group (J), the traditional Chinese medicine and food homologous mixture group (Y), and the postbiotic preparation and traditional Chinese medicine and food homologous mixture composition group (Z) were significantly lower than those in the model group (H). Among them, the TG / HDL ratio of mice in the heat-inactivated bacterial cell group (J) was the lowest ( Figure 14 ), indicating that postbiotic preparations, traditional Chinese medicine and food homologous mixtures, and their compositions can all significantly reduce the cardiovascular risk factors in model mice.

[0139] Nitric oxide (NO) is an important signaling molecule, especially playing a key role in vascular endothelial function and metabolic regulation. The results found that the serum NO level in mice in the cardiovascular and cerebrovascular injury model group (H) induced by a high-fat and high-cholesterol diet was significantly lower than that in the control group (C) mice. A high-fat and high-cholesterol diet may cause endothelial cell dysfunction, leading to a decrease in the activity of endothelial nitric oxide synthase (eNOS), thereby reducing the production of NO, impairing vascular endothelial function, and disrupting homeostasis. Compared with the model group, the serum NO levels in mice in the traditional Chinese medicine and food homologous mixture group (Y) and the postbiotic preparation and traditional Chinese medicine and food homologous mixture composition group (Z) increased, being extremely significantly higher than those in the model group, and the serum NO level in mice in the postbiotic preparation and traditional Chinese medicine and food homologous mixture composition group was the highest ( Figure 15 ), indicating that the combination of postbiotics and traditional Chinese medicine and food homologous mixtures helps alleviate the vascular function impairment induced by a high-fat and high-cholesterol diet, promote vasodilation and blood flow improvement, and has great potential for protecting cardiovascular health.

[0140] 6. Effects of postbiotic preparations and traditional Chinese medicine and food homologous mixture compositions on myocardial tissue injury and fibrosis.

[0141] The results of pathological section staining showed that after 12 weeks of induction with a high-fat and high-cholesterol diet, the myocardial cell nuclei of mice in the control group (C) were blue, the myocardial cells were arranged neatly, the muscle bundles were full, and the cytoplasm was bright red, while the myocardium of mice in the model group (H) was disordered, with inflammatory cell infiltration and ventricular damage. Compared with the model group, the appearance of myocardial cells in mice in the heat-inactivated bacterial cell group (J), the traditional Chinese medicine and food homologous mixture group (Y), and the postbiotic preparation and traditional Chinese medicine and food homologous mixture composition group (Z) was normal, the inflammatory cell infiltration was significantly reduced, and the myocardial cells were arranged neatly ( Figure 16 ).

[0142] Myocardial fibrosis usually presents as the proliferation of blue collagen fibers, mainly located in the cardiac interstitium or the subendocardial layer. The staining results of pathological sections showed that the hearts of mice in the high-fat and high-cholesterol diet-induced model group (H) showed obvious collagen fiber deposition under Masson staining. Compared with the control group (C) mice, the hearts of the model group (H) mice showed a more obvious degree of fibrosis, which may further affect the cardiac contractile function. Compared with the model group, the degree of blue fibrosis of myocardial cells in the heat-inactivated bacteria group (J), the food and medicine homologous mixture group (Y), and the postbiotic preparation and food and medicine homologous mixture composition group (Z) mice was reduced ( Figure 17 ).

[0143] 7. Effects of postbiotic preparation and food and medicine homologous mixture composition on the blood-brain barrier and neuronal damage.

[0144] Nissl staining is mainly used to observe the cell bodies of nerve cells, especially the distribution of rough endoplasmic reticulum (i.e., Nissl bodies), which can reveal the degree of neuronal damage in model mice and evaluate the specific effects of high-fat and high-cholesterol diet on nervous system health. After 12 weeks of high-fat and high-cholesterol diet induction, the Nissl bodies of the model group (H) mice were significantly reduced and their morphology changed, showing swelling of the rough endoplasmic reticulum or irregular structure ( Figure 18 B in), indicating that high-fat and high-cholesterol diet induced neuronal damage and degeneration in the brains of mice. It is worth noting that the degree of damage to the Nissl bodies of the heat-inactivated bacteria group (J), the food and medicine homologous mixture group (Y), and the postbiotic preparation and food and medicine homologous mixture composition group (Z) mice was improved, and the number of Nissl bodies of the postbiotic preparation and food and medicine homologous mixture composition group (Z) mice significantly recovered and their morphology also returned to normal ( Figure 18 E in), indicating that postbiotics and food and medicine homologous mixture composition have important positive effects on the nervous system health of model mice.

[0145] After 12 weeks of high-fat and high-cholesterol diet induction, the levels of IL-1β and TNF-α in the brains of the model group (H) mice were significantly higher than those of the control group (C) mice, indicating that high-fat and high-cholesterol diet induced a systemic inflammatory response in mice, and this inflammatory response may affect the central nervous system. Long-term high-fat and high-cholesterol diet may also lead to a decline in blood-brain barrier function, which makes peripheral immune factors (such as IL-1β and TNF-α) more likely to enter the brain, thus exacerbating the local inflammatory response.

[0146] It is worth noting that the levels of IL-1β and TNF-α in the brains of the heat-inactivated bacteria group (J), the food and medicine homologous mixture group (Y), and the postbiotic preparation and food and medicine homologous mixture composition group (Z) mice were significantly lower than those of the model group (H) mice ( Figure 19) indicating that the postbiotic and the medicine and food homologous mixture composition have a significant improvement effect on the blood-brain barrier repair and brain inflammation level of model mice.

[0147] 8. Effects of postbiotic preparations and medicine and food homologous mixture compositions on intestinal flora disorders in model mice.

[0148] 16S rRNA gene microbial sequencing: Total DNA in feces was extracted using the QIAamp DNA Stool minikit kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. The total DNA content was normalized to 1 ng / μL. The V3-V4 region of 16S rRNA was amplified using universal primers. The upstream primer was 341F (5’-CCTACGGGNGGCWGCAG-3’, SEQ ID NO.1), and the downstream primer was 802R (5’-TACNVGGGTATCTAATCC-3’, SEQ ID NO.2), where N, W, and V used the IUPAC (International Union of Pure and Applied Chemistry) nucleotide codes to represent base polymorphisms; N represents any base (A / T / C / G) and is applicable to cases where there may be variations at this site; W represents A or T to ensure adaptation to 16S rRNA sequences of different bacteria; V represents A, C, or G; the PCR reaction system was as follows: 10 ng of pure DNA, 15 μL of high-fidelity DNA polymerase and PCR premix, 200 nmol / L of upstream and downstream primers, nuclease-free water, and the final volume was 30 μL. The PCR cycling conditions included an initial denaturation at 98 °C for 1 min, 30 cycles of 98 °C for 10 s, 50 °C for 30 s, and 72 °C for 5 min. The PCR products were quantified, mixed in equimolar ratios, and then purified and sequenced using the Illumina MiSeq platform with a sequencing depth of at least 20,000 sequences per sample.

[0149] The QIIME analysis software uses FLASH to merge sequences. The sequences with dual ends added are clustered into operational taxonomic units (OTUs) with 97% sequence similarity using the GreenGenes dataset and the UPARSE algorithm. The representative sequences of each OTU are aligned, and then the RDP classifier is used to annotate the taxonomic information of each representative sequence. The analysis includes each taxonomic level (such as phylum, class, order, family, genus, etc.). In-house Perl scripts are used to analyze the α-diversity within samples and the β-diversity between samples. Principal coordinate analysis (PCoA) using the Unweightedunifrac method is used to evaluate the differences between experimental samples. All samples are used to calculate α-diversity, including richness and diversity. The taxonomic information of 16S rRNA gene sequence information is analyzed using UCLUST version 1.2.22 with a 90% confidence interval for the Silva119 16S rRNA dataset.

[0150] By analyzing the microbial community structure in the intestines of mice in different groups, such as Figure 20 shown, after 12 weeks of induction with a high-fat and high-cholesterol diet, the relative abundances of Escherichia-Shigella and Parasutterella in the intestines of mice in the model group (H) increased significantly ( Figure 20 A, B). The increase in bacteria of the genus Escherichia-Shigella, especially in the case of glycolipid metabolism disorders, is related to the inflammatory response in the intestine, can trigger the inflammatory response of the intestinal mucosa, and will further affect the intestinal barrier function and metabolic health of the host. The increase in the abundance of Parasutterella is related to the metabolic health of the host, and excessive consumption of high-fat and ultra-processed foods will lead to an increase in the abundance of Parasutterella. However, the relative abundances of Escherichia-Shigella and Parasutterella in the intestines of mice in the heat-inactivated bacterial group (J), the traditional Chinese medicine and food homologous mixture group (Y), and the postbiotic preparation and traditional Chinese medicine and food homologous mixture combination group (Z) all decreased significantly, indicating that postbiotics and traditional Chinese medicine and food homologous mixtures have a potential alleviating effect on high-fat and high-cholesterol diet-induced intestinal inflammation and dysbiosis.

[0151] Notably, the relative abundance of Clostridium sensu stricto 1 in the intestines of mice in the model group (H) was significantly lower than that in the control group (C). Clostridium sensu stricto 1 is an anaerobic bacterium that regulates bile acids in the intestine and can affect the host's bile acid levels, intestinal health, and metabolic function by changing the composition and metabolic pathways of bile acids in the intestine. The relative abundances of Clostridium sensu stricto 1 in the intestines of mice in the heat-inactivated bacterial cell group (J), the traditional Chinese medicine and food homologous mixture group (Y), and the postbiotic preparation and traditional Chinese medicine and food homologous mixture composition group (Z) all increased significantly, suggesting that postbiotic preparations and traditional Chinese medicine and food homologous mixtures may regulate the glycolipid metabolism of model mice through bile acid metabolism.

[0152] PICRUSt analysis was used to predict microbial functions, and the abundances of the annotated OTUs were used with the LEfSe online tool to identify the highly representative bacterial communities in different treatment groups. The functional clustering differences of the intestinal microbiota of mice in different groups were further investigated, such as Figure 21 shown. After 12 weeks of induction with a high-fat and high-cholesterol diet, the tissue signal transduction pathway, response regulators of the OmpR family, XerD-specific recombinase, bacterial RNA polymerase, glycosyltransferase, sodium ion-driven multidrug efflux pump, ABC-type multidrug transport system, AraC-type DNA-binding domain, and DNA-binding transcriptional regulatory factor pathway of the AcrR family in the intestinal microbiota of mice in the model group (H) were all significantly downregulated. These functional prediction results showed that some pathways in the intestinal microbiota changed under the influence of a high-fat and high-cholesterol diet, especially the pathways related to anti-pathogenic bacterial infection, stress response, cell wall synthesis, signal transduction, and transcriptional regulation.

[0153] Notably, the expression of these pathways in the intestines of mice in the heat-inactivated bacterial cell group (J) and the postbiotic preparation and traditional Chinese medicine and food homologous mixture composition group (Z) increased, indicating that postbiotic preparations, postbiotics, and traditional Chinese medicine and food homologous mixture compositions can enhance the adaptability of the intestinal microbiota during glycolipid metabolism disorders, chronic inflammation, or drug stress, further suggesting that postbiotic preparations, postbiotics, and traditional Chinese medicine and food homologous mixture compositions may play important roles in anti-infection, environmental adaptation, and interaction with the host.

[0154] 9. The postbiotic preparation and traditional Chinese medicine and food homologous mixture composition regulate the glycolipid metabolism of model mice by inhibiting bile acid reabsorption.

[0155] Through the analysis of the intestinal microbiota sequencing results, it was found that the abundance of bile acid-related bacteria increased significantly. Therefore, the study further verified whether the postbiotics and the composition of food and medicine homologous mixtures play a role in improving hyperlipidemia and the resulting cognitive impairment in mice with metabolic dysfunction by regulating the key pathway of bile acid metabolism by measuring the bile acid levels in the liver, ileum, and serum of mice in different groups.

[0156] After 12 weeks of induction with a high-fat and high-cholesterol diet, the total bile acid level in the liver of mice in the model group (H) was significantly higher than that in the control group (C) mice, indicating that the high-fat and high-cholesterol diet induced an increase in bile acid synthesis in the liver of mice. The total bile acid levels in the liver tissues of mice in the heat-inactivated bacterial group (J), the food and medicine homologous mixture group (Y), and the postbiotics and food and medicine homologous mixture composition group (Z) were all significantly lower than those in the model group (H) mice. Among them, the total bile acid level in the liver of mice in the postbiotics and food and medicine homologous mixture composition group (Z) was the lowest.

[0157] The level of CYP7A1 enzyme in the liver of mice in the model group (H) was significantly higher than that in the control group (C) mice, indicating that the high-fat and high-cholesterol diet induced an increase in bile acid synthesis in the liver of mice. There was no significant difference between the heat-inactivated bacterial group (J), the food and medicine homologous mixture group (Y), and the model group (H) mice, while the level of CYP7A1 enzyme in the liver of mice in the postbiotics and food and medicine homologous mixture composition group (Z) was significantly lower than that in the model group (H) mice ( Figure 22 )

[0158] The results showed that the total bile acid level in the ileum tissue of mice in the model group (H) was significantly higher than that in the control group (C) mice, indicating that the high-fat and high-cholesterol diet induced an enhanced ability of the ileum in mice to reabsorb bile acids from the blood. The total bile acid levels in the ileum tissues of mice in the heat-inactivated bacterial group (J), the food and medicine homologous mixture group (Y), and the postbiotics and food and medicine homologous mixture composition group (Z) were all significantly lower than those in the model group (H) mice. Among them, the total bile acid level in the ileum tissue of mice in the postbiotics and food and medicine homologous mixture composition group (Z) was the lowest ( Figure 23 )

[0159] The total bile acid level in the serum of mice in the model group (H) was significantly higher than that in the control group (C) mice, indicating that the bile acids synthesized in increased amounts in the liver of mice induced by the high-fat and high-cholesterol diet entered the blood circulation. There was no significant difference between the food and medicine homologous mixture group (Y) and the model group (H) mice, while the total bile acid levels in the serum of mice in the heat-inactivated bacterial group (J) and the postbiotics and food and medicine homologous mixture composition group (Z) were significantly lower than those in the model group (H) mice.

[0160] In summary, the postbiotics and the composition of food and medicine homologous mixtures regulate the glucose and lipid metabolism of model mice by inhibiting bile acid reabsorption.

[0161] Comparative Example 1: Deleting the main components in the raw materials of the medicine-food homologous mixture has a significant impact on lipid-lowering activity.

[0162] By measuring the difference in the ability of the probiotic preparation (in the form of heat-inactivated bacteria) and the medicine-food homologous mixture before and after deleting the main components (ginseng, longan pulp, lotus leaf, poria cocos) to bind to bile salts in an in vitro simulated intestinal environment, the impact of the main components in the medicine-food homology on lipid-lowering activity was then judged.

[0163] 1. Referring to the method of Example 1, heat-inactivated bacteria, a medicine-food homologous mixture, and a medicine-food homologous mixture after deleting the main components were prepared. The heat-inactivated bacteria and the two medicine-food homologous mixtures were mixed at a mass ratio of 2:1 to obtain different probiotic preparation and medicine-food homologous mixture compositions.

[0164] 2. Draw the standard curves of sodium glycocholate and sodium taurocholate, and refer to Example 2 for measuring the ability to bind to bile salts in an in vitro simulated intestinal environment.

[0165] The results showed that: As can be seen from Figure 24 A and B in, after deleting the main components, the bile salt-binding ability of the probiotic preparation and the medicine-food homologous mixture composition decreased significantly, indicating that the main components play an important role in lipid-lowering activity.

[0166] Comparative Example 2: Selecting other probiotic preparations of Bifidobacterium infantis subspecies and combining them with the above-mentioned medicine-food homologous raw material components has a significant impact on lipid-lowering activity.

[0167] By measuring the difference in the ability of other probiotic preparations (in the form of heat-inactivated bacteria) of Bifidobacterium infantis subspecies (ATCC15697, BI1-4, BI1-9, BI3-5) and the medicine-food homologous mixture to bind to bile salts in an in vitro simulated intestinal environment, the impact on lipid-lowering activity was then judged. The ATCC15697 is a standard strain, and the other 3 Bifidobacterium infantis subspecies are strains self-isolated and preserved in the laboratory.

[0168] 1. Referring to the method of Example 1, heat-inactivated bacteria and a medicine-food homologous mixture were prepared. The heat-inactivated bacteria and the two medicine-food homologous mixtures were mixed at a mass ratio of 2:1 to obtain different probiotic preparation and medicine-food homologous mixture compositions.

[0169] 2. Draw the standard curves of sodium glycocholate and sodium taurocholate, and refer to Example 2 for measuring the ability to bind to bile salts in an in vitro simulated intestinal environment.

[0170] The results showed that: As can be seen from Figure 25As shown in A and B, there are significant differences in the bile salt binding abilities of different Bifidobacterium longum infantis subspecies when combined with edible and medicinal components, and only NKU FB3-14 has the strongest lipid-lowering activity when combined with edible and medicinal components.

[0171] Although the above embodiment provides a detailed description of the present invention, it is only a part of the embodiments of the present invention, not all of the embodiments. People can also obtain other embodiments based on this embodiment without creativity, and these embodiments all fall within the scope of protection of the present invention.

Claims

1. A composition of postbiotics preparation and a mixture of medicine and food homology of Bifidobacterium longum subsp. infantis, characterized in that, A postbiotic preparation and a medicine-food homologous mixture comprising Bifidobacterium longum subsp. Infantis NKUFB3-14; The preservation number of the Bifidobacterium longum subsp. infantis NKU FB3-14 is CGMCC No. 25762; the postbiotics preparation of the Bifidobacterium longum subsp. infantis NKU FB3-14 includes the heat-inactivated product of the bacterial liquid of the Bifidobacterium longum subsp. infantis NKU FB3-14, the heat-inactivated product of the bacterial cells in the bacterial liquid, or the heat-inactivated product of the supernatant in the bacterial liquid; the concentration of the Bifidobacterium longum subsp. infantis NKU FB3-14 in the bacterial liquid of the Bifidobacterium longum subsp. infantis NKU FB3-14 is 1×10 8 ~3×10 9 CFU / mL; By mass, the medicine-food homologous mixture comprises the following raw materials: 10-20 parts of ginseng, 10-20 parts of longan pulp, 10-20 parts of poria cocos, 10-20 parts of lotus leaf, 5-15 parts of Chinese yam, 5-15 parts of coix seed, 5-15 parts of polygonatum odoratum, 5-15 parts of malt, 5-15 parts of tangerine peel, 5-15 parts of white hyacinth bean and 4-6 parts of hawthorn.

2. The composition according to claim 1, wherein The postbiotic preparation of *Bifidobacterium longum subsp. infantis* NKUFB3-14 comprises the heat-inactivated product of the bacterial cells in the bacterial liquid of *Bifidobacterium longum subsp. infantis* NKU FB3-14; the heat-inactivated product is also subjected to vacuum freeze-drying; the concentration of *Bifidobacterium longum subsp. infantis* NKUFB3-14 in the bacterial liquid of *Bifidobacterium longum subsp. infantis* NKU FB3-14 is 2×10 9 ~3×10 9 CFU / mL.

3. The composition according to claim 2, characterized in that, The mass ratio of the postbiotic preparation of Bifidobacterium longum subsp. Infantis NKUFB3-14 to the medicine-food homologous mixture is (2-4):

1.

4. Use of the composition according to any one of claims 1-3 in the preparation of a food.

5. The application according to claim 4, characterized in that, The food includes foods that help improve glycolipid metabolism.

6. The application according to claim 5, characterized in that, The glycolipid metabolism includes glycolipid metabolism caused by a high-fat and high-cholesterol diet.

7. The application according to claim 5 or 6, characterized in that, The improvement of glycolipid metabolism includes one or more of reducing body weight, controlling body weight gain, reducing blood glucose content, reducing triglyceride content, reducing cholesterol content, reducing appetite, increasing food energy conversion efficiency, reducing organ weight, reducing epididymal fat content, inhibiting intestinal fat absorption, inhibiting intestinal cholesterol absorption, reducing adipocyte area, increasing serum leptin level, protecting liver cells, regulating bile acid metabolism, inhibiting bile acid reabsorption and improving intestinal flora.

8. The application according to claim 7, wherein The organ includes the liver and / or the epididymis.

9. Use of the composition according to any one of claims 1-3 in the preparation of a drug for preventing, treating and / or alleviating a disease; the disease includes one or more of obesity, glycolipid metabolism dysfunction, intestinal inflammation, intestinal flora disorder, hyperlipidemia and cardiovascular and cerebrovascular diseases.

10. The application according to claim 9, characterized in that Preventing, treating and / or alleviating cardiovascular and cerebrovascular diseases includes one or more of reducing the level of cardiovascular risk factors, increasing the level of NO in serum, reducing cardiovascular and cerebrovascular damage, alleviating impaired vascular function, promoting vasodilation and blood flow improvement, inhibiting myocardial cell fibrosis, protecting the nervous system, repairing the blood-brain barrier and improving brain inflammation.

Images